| Jun 19 |
Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
|
| Jun 19 |
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
|
| Jun 17 |
Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment
|
| Jun 17 |
Nurix releases promising phase 1 data on NX-5948 for chronic lymphocytic leukemia
|
| Jun 16 |
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
|
| Jun 12 |
Nurix Therapeutics files for mixed shelf securities offering
|
| Jun 10 |
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
|
| May 29 |
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
| May 28 |
Nurix Therapeutics appoints Paula O’Connor as chief medical officer
|
| May 28 |
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
|
